IRIS
VOGRIG, Alberto
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.771
NA - Nord America 1.825
EU - Europa 969
SA - Sud America 552
AF - Africa 68
OC - Oceania 3
Totale 6.188
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.758
SG - Singapore 1.573
BR - Brasile 456
CN - Cina 409
IT - Italia 348
HK - Hong Kong 272
VN - Vietnam 224
RU - Federazione Russa 132
DE - Germania 124
KR - Corea 75
IE - Irlanda 72
IN - India 61
AR - Argentina 49
GB - Regno Unito 48
FR - Francia 39
FI - Finlandia 32
UA - Ucraina 30
NL - Olanda 29
AT - Austria 28
CA - Canada 27
MX - Messico 26
ID - Indonesia 23
TG - Togo 23
JP - Giappone 20
SE - Svezia 19
BD - Bangladesh 17
EC - Ecuador 17
TR - Turchia 16
ES - Italia 15
IQ - Iraq 11
ZA - Sudafrica 11
CO - Colombia 10
MA - Marocco 8
PK - Pakistan 8
PL - Polonia 8
BE - Belgio 7
KZ - Kazakistan 7
SA - Arabia Saudita 7
LT - Lituania 6
NP - Nepal 6
PT - Portogallo 6
PY - Paraguay 6
TN - Tunisia 6
CZ - Repubblica Ceca 5
EG - Egitto 5
TH - Thailandia 5
TW - Taiwan 5
AE - Emirati Arabi Uniti 4
AZ - Azerbaigian 4
DZ - Algeria 4
JM - Giamaica 4
BG - Bulgaria 3
CL - Cile 3
KE - Kenya 3
KG - Kirghizistan 3
LV - Lettonia 3
OM - Oman 3
PE - Perù 3
PH - Filippine 3
SN - Senegal 3
UY - Uruguay 3
VE - Venezuela 3
AU - Australia 2
BH - Bahrain 2
BO - Bolivia 2
CH - Svizzera 2
CU - Cuba 2
DO - Repubblica Dominicana 2
GR - Grecia 2
IL - Israele 2
MD - Moldavia 2
UZ - Uzbekistan 2
AL - Albania 1
AM - Armenia 1
AO - Angola 1
BB - Barbados 1
BW - Botswana 1
BY - Bielorussia 1
CR - Costa Rica 1
CY - Cipro 1
DK - Danimarca 1
ET - Etiopia 1
GE - Georgia 1
HR - Croazia 1
HT - Haiti 1
HU - Ungheria 1
IR - Iran 1
JO - Giordania 1
KH - Cambogia 1
LB - Libano 1
LK - Sri Lanka 1
LU - Lussemburgo 1
MK - Macedonia 1
MY - Malesia 1
NI - Nicaragua 1
NZ - Nuova Zelanda 1
PA - Panama 1
RO - Romania 1
SC - Seychelles 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 6.186
Salva come PNG Salva come JPEG
Città #
Singapore 436
Hong Kong 268
Ashburn 251
Beijing 209
Fairfield 136
Boardman 106
Ho Chi Minh City 77
Chandler 75
Seoul 75
Hefei 74
Los Angeles 73
Dublin 72
Trieste 71
Woodbridge 63
Seattle 60
Houston 57
Redondo Beach 54
Dallas 52
Munich 49
São Paulo 46
Wilmington 45
Cambridge 41
Hanoi 40
Milan 38
New York 38
Buffalo 34
Ogden 29
Belluno 25
Nuremberg 24
Venezia 24
Dearborn 23
Lomé 23
Princeton 20
Ann Arbor 19
Frankfurt am Main 19
Hyderabad 19
Dong Ket 17
Udine 17
Mexico City 16
Tavagnacco 16
Lappeenranta 14
Rio de Janeiro 14
Amsterdam 13
London 13
Helsinki 12
Jacksonville 12
Montreal 12
Redmond 12
Da Nang 11
Orem 11
Santa Clara 11
Tokyo 11
Poplar 10
Biên Hòa 9
Chennai 9
Düsseldorf 9
Vienna 9
Chicago 8
Guarulhos 8
Izmir 8
Mumbai 8
New Delhi 8
Rome 8
San Diego 8
Belo Horizonte 7
Boston 7
Brussels 7
Denver 7
Goiânia 7
Guayaquil 7
Porto Alegre 7
San Francisco 7
Bologna 6
Council Bluffs 6
Haiphong 6
Johannesburg 6
Norwalk 6
Sorocaba 6
Stockholm 6
The Dalles 6
Brooklyn 5
Codroipo 5
Curitiba 5
Fayetteville 5
Franca 5
Guangzhou 5
Jakarta 5
Lauterbourg 5
Lisbon 5
Ninh Bình 5
Nove 5
Phoenix 5
Shanghai 5
Toronto 5
Turku 5
Atlanta 4
Bangkok 4
Beppu 4
Betim 4
Brasília 4
Totale 3.278
Salva come PNG Salva come JPEG
Nome #
Intra-carotid self-injection of alprazolam: an unusual cause of unilateral multiembolic stroke 199
Tacrolimus-induced severe headache associated with diffuse leukoencephalopathy: Evidence for an immune-mediated pathogenesis 156
Epidemiology of autoimmune versus infectious encephalitis 153
Effect of thymectomy on refractory autoimmune status epilepticus 131
Peculiar EEG signatures, ictal drinking and long-term follow-up in anti-LGI1 encephalitis 130
Epidemiology of paraneoplastic neurological syndromes: a population-based study 129
Epilepsia partialis continua revealing idelalisib-associated PML-IRIS: clinical and pathological features 128
Seizure specificities in patients with antibody-mediated autoimmune encephalitis 112
Serum markers as predictors of immune checkpoint inhibitors (ICI) related adverse events in a real-world scenario 112
Stroke-Like Presentation of Paraneoplastic Cerebellar Degeneration: a Single-Center Experience and Review of the Literature 98
Back to the future: encephalitis lethargica as an autoimmune disorder? 88
Acute disseminated encephalomyelitis after SARS-CoV-2 vaccination 88
Reply to "Guillain‑Barré syndrome in the COVID‑19 era another occasional cluster?": Insights from two distinct clusters of Guillain–Barré syndrome detected in Europe in the COVID-19 era 85
Efficacy of Perampanel in Refractory and Super-Refractory Status Epilepticus with Suspected Inflammatory Etiology: A Case Series 78
Neurologic Adverse Events of Immune Checkpoint Inhibitors: A Systematic Review 77
Consensus Paper: Latent Autoimmune Cerebellar Ataxia (LACA) 76
Causality in COVID-19-associated stroke: a uniform case definition for use in clinical research 76
Central nervous system adverse events of immune checkpoint inhibitors 75
Stroke in patients with SARS-CoV-2 infection: case series 75
Paraneoplastic neurological syndromes associated with renal or bladder cancer: case series and PRISMA-IPD systematic review 75
Response to Letter to the Editor on the article “Acute disseminated encephalomyelitis after SARS-CoV-2 vaccination” 73
Anti-Hu Antibodies in Patients With Neurologic Side Effects of Immune Checkpoint Inhibitors 72
Anti-CASPR2 clinical phenotypes correlate with HLA and immunological features 71
Seizures, Epilepsy, and NORSE Secondary to Autoimmune Encephalitis: A Practical Guide for Clinicians 71
Cerebellar Ataxia With Anti-DNER Antibodies: Outcomes and Immunologic Features 69
Sudden unexpected death in epilepsy and ictal asystole in patients with autoimmune encephalitis: a systematic review 69
HLA and immunological features of SARS-CoV-2-induced Guillain-Barré syndrome 69
Perampanel as add-on therapy in epilepsies with known etiology: A single center experience with long-term follow-up 68
Unclear association between COVID-19 and Guillain-Barré syndrome 67
Bornavirus associated with fatal human encephalitis 66
Application of the anti-IgLON5 disease composite score to assess severity, clinical course, and mortality in a French cohort 66
Eating reflex epilepsy of presumed autoimmune etiology after SARS-CoV-2 vaccination 65
18F-FDG PET brain findings in disease-discordant monozygotic mosaic twins with Cri du Chat (5p-) syndrome 64
Editorial: Neuroglial antibodies: From clinical associations to pathophysiological investigations 63
Movement disorders in oncology: From clinical features to biomarkers 62
Central nervous system complications associated with immune checkpoint inhibitors 62
Adenovirus COVID-19 Vaccines and Guillain–Barré Syndrome with Facial Paralysis 62
Argonaute Autoantibodies as Biomarkers in Autoimmune Neurologic Diseases 62
Cranial Nerve Disorders Associated With Immune Checkpoint Inhibitors 61
Early Immunotherapy and Longer Corticosteroid Treatment Are Associated With Lower Risk of Relapsing Disease Course in Pediatric MOGAD 61
A systematic study of stereotypy in epileptic seizures versus psychogenic seizure-like events 61
Anti-Hu-associated paraneoplastic syndromes triggered by immune-checkpoint inhibitor treatment 60
Central nervous system immune-related disorders after SARS-CoV-2 vaccination: a multicenter study 60
Real-Life Evaluation of the MOGAD Diagnostic Criteria: Application Challenges and Discrepancies 59
Motor neuron involvement in anti-Ma2-associated paraneoplastic neurological syndrome 57
Immunopathogenesis and proposed clinical score for identifying Kelch-like protein-11 encephalitis 57
Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes 56
Anti-Ma-associated encephalomyeloradiculopathy in a patient with pleural mesothelioma 56
Bilateral carotid artery dissection in a SARS-CoV-2 infected patient: causality or coincidence? 55
Prognostic Value of Persistent CSF Antibodies at 12 Months in Anti-NMDAR Encephalitis 54
Immune and Genetic Signatures of Breast Carcinomas Triggering Anti-Yo-Associated Paraneoplastic Cerebellar Degeneration 54
Neurological adverse events of immune checkpoint inhibitors and the development of paraneoplastic neurological syndromes 53
SARS-CoV-2-related encephalitis with prominent parkinsonism: clinical and FDG-PET correlates in two patients 53
Evaluation and treatment approaches for neurological post-acute sequelae of COVID-19: A consensus statement and scoping review from the global COVID-19 neuro research coalition 53
Proceedings of the “International Congress on Structural Epilepsy & Symptomatic Seizures” (STESS, Gothenburg, Sweden, 29–31 March 2023) 53
Reader Response: Prolonged Unconsciousness Following Severe COVID-19 53
Prediction, prevention, and precision treatment of immune checkpoint inhibitor neurological toxicity using autoantibodies, cytokines, and microbiota 53
Transient Neurological Symptoms Preceding Cerebellar Ataxia with Glutamic Acid Decarboxylase Antibodies 52
Increased frequency of anti-Ma2 encephalitis associated with immune checkpoint inhibitors 52
Stroke in patients with COVID-19: Clinical and neuroimaging characteristics 52
Characterization and management of neurological adverse events during immune-checkpoint inhibitors treatment: an Italian multicentric experience 52
Associations between HLA and autoimmune neurological diseases with autoantibodies 51
Clinical and Prognostic Value of Immunogenetic Characteristics in Anti-LGI1 Encephalitis 51
Nystagmus and lower extremity hyperalgesia after colectomy 50
Core cerebrospinal fluid biomarker profile in anti-LGI1 encephalitis 49
Novelties in Autoimmune and Paraneoplastic Cerebellar Ataxias: Twenty Years of Progresses 49
Glioblastoma as differential diagnosis of autoimmune encephalitis 47
Distinctive clinical presentation and pathogenic specificities of anti-AK5 encephalitis 47
How to diagnose and manage neurological toxicities of immune checkpoint inhibitors: an update 47
Paraneoplastic encephalitis: clinically based approach on diagnosis and management 47
Immune Checkpoint Inhibitor-Related Cerebellar Toxicity: Clinical Features and Comparison with Paraneoplastic Cerebellar Ataxia 46
Different Genetic Signatures of Small-Cell Lung Cancer Characterize Anti-GABABR and Anti-Hu Paraneoplastic Neurological Syndromes 46
Cytokine dynamics and targeted immunotherapies in autoimmune encephalitis 46
Distinguishing seizures in autoimmune limbic encephalitis from mesial temporal lobe epilepsy with hippocampal sclerosis: Clues of a temporal plus network 45
Postencephalitic epilepsy in children and adults: Etiology matters 45
Glial Fibrillary Acidic Protein Autoimmunity: A French Cohort Study 45
Role of LGI1 protein in synaptic transmission: From physiology to pathology 45
Prognosis of status epilepticus in adults: recent advances and future directions 44
Distinct movement disorders in contactin-associated-protein-like-2 antibody-associated autoimmune encephalitis 44
Probable dysimmune epilepsia partialis continua manifesting as epileptic moving toes syndrome: electroclinical features of a challenging case 44
Immunomodulation in the acute phase of autoimmune encephalitis 44
Comparative Study of Paraneoplastic and Nonparaneoplastic Autoimmune Encephalitis With GABA B R Antibodies 44
Neuroimmune disorders in COVID-19 44
Corticospinal tract hyperintensity in patients with LGI1-antibody encephalitis and other central nervous system disorders with neuroglial antibodies 43
Pathophysiology of paraneoplastic and autoimmune encephalitis: genes, infections, and checkpoint inhibitors 43
Neurological outcomes in immune checkpoint inhibitor-related neurotoxicity 42
Prevalence and Trajectories of Post-COVID-19 Neurological Manifestations: A Systematic Review and Meta-Analysis 42
Dramatic response to delayed treatment with tocilizumab in new-onset refractory status epilepticus 42
Early-Stage Contactin-Associated Protein-like 2 Limbic Encephalitis: Clues for Diagnosis 41
Spatial and Ecological Factors Modulate the Incidence of Anti-NMDAR Encephalitis—A Systematic Review 41
Clinical Course of Neurologic Adverse Events Associated With Immune Checkpoint Inhibitors. Focus on Chronic Toxicities 39
Predictors and Clinical Characteristics of Relapses in LGI1-Antibody Encephalitis 38
SOX1 antibody-related paraneoplastic neurological syndromes: clinical correlates and assessment of laboratory diagnostic techniques 38
Revisiting anti-Hu paraneoplastic autoimmunity: phenotypic characterization and cancer diagnosis 38
Clinical spectrum and diagnostic pitfalls of neurologic syndromes with Ri antibodies 38
Familial autoimmunity in neurological patients with GAD65 antibodies: an interview-based study 38
Diagnostic yield of commercial immunodots to diagnose paraneoplastic neurologic syndromes 37
Epidemiology of paraneoplastic neurologic syndromes and autoimmune encephalitides in France 35
Epileptic phenotypes in autoimmune encephalitis: From acute symptomatic seizures to autoimmune-associated epilepsy 34
Value of Onconeural Antibodies in Checkpoint Inhibitor-Related Toxicities 32
Totale 6.300
Salva come PNG Salva come JPEG
Categoria #
all - tutte 34.768
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 34.768
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021182 0 0 0 0 0 24 17 23 46 14 25 33
2021/2022183 9 18 37 6 2 0 13 4 3 20 48 23
2022/2023528 20 18 3 19 176 179 4 8 31 6 17 47
2023/2024343 28 22 5 24 40 18 9 31 44 57 29 36
2024/20252.297 85 140 93 70 71 83 110 104 294 240 404 603
2025/20262.532 349 406 415 552 538 272 0 0 0 0 0 0
Totale 6.569